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Abstract
Hepatic fibrosis results from excess extracellular matrix produced primarily by hepatic stellate cells (HSC). In response to injury, HSC
differentiate to a myofibroblastic phenotype expressing smooth muscle actin and fibrillar collagens. Relaxin is a polypeptide hormone
shown to have antifibrotic effects in fibrosis models. In this study, activated HSC from rat liver were treated with relaxin to determine if
relaxin can reverse markers of HSC activation. Relaxin treatment resulted in a decrease in the expression of smooth muscle actin, but had
no effect on cell proliferation rate. The levels of total collagen and type I collagen were reduced, while the synthesis of new collagen was
inhibited. Furthermore, relaxin caused an increase in the expression and secretion of rodent interstitial collagenase (MMP-13), but there
was no effect on the gelatinases MMP-2 or MMP-9. Relaxin also increased secretion of TIMP-1 and TIMP-2. The effective concentration
of relaxin to induce these effects was consistent with action through the relaxin receptor. In conclusion, relaxin reversed markers of the
activated phenotype of HSC including the production of fibrillar collagen. At the same time, the activity of a fibrillar collagenase was
increased. These data suggest that relaxin not only inhibits HSC properties that contribute to the progression of hepatic fibrosis, but also
promotes the clearance of fibrillar collagen. Therefore, relaxin may be a useful approach in the treatment of hepatic fibrosis.
# 2003 Elsevier Inc. All rights reserved.
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1. Introduction
The central event in the processes leading to liver fibrosis
is the activation of HSC (see [1–3] for recent reviews). In
the normal state HSC are quiescent cells that store lipid in
the form of retinoids, and produce low amounts of ECM,
mostly type IV collagen. Liver injury results in a change in
HSC from a quiescent state to an ‘‘activated’’ myofibro-
blastic phenotype characterized by loss of retinoid stores,
increased proliferation, contractility, and expression of a-
smooth muscle actin (SMA) [4,5]. In addition, reflecting the
changes seen in fibrotic liver, the production of ECM
components and their degrading enzymes also changes
drastically. Normally, there is a highly regulated balance
between production and degradation of ECM components
to maintain the extracellular architecture. After HSC acti-
vation, overall collagen levels increase greatly, with type I
collagen as the predominant form [6]. There are also
widespread changes in the matrix-degrading enzymes
and their regulators. The expression of interstitial collage-
nases that degrade fibrillar collagen (MMP-1 and MMP-13)
is reduced [7], while conversely, the activity of MMP-2
(gelatinase A) is upregulated [8,9] resulting in increased
degradation of nonfibrillar (types II and IV) collagens and
decreased degradation of fibrillar (types I and III) collagens.
At the same time, the expression of the tissue inhibitor of
metalloproteinases (TIMP) is increased [10], further shift-
ing the balance away from degradation and toward accu-
mulation of collagen. Therefore, the reduction or reversal of
HSC activation is an attractive therapeutic target in the
treatment of hepatic fibrosis.
Relaxin is a member of the insulin family of polypeptide
hormones (see [11,12] for review), although it has no
affinity for the insulin receptor. Although many physiolo-
gical functions of relaxin are being identified, the relaxin
receptor has only recently been characterized at the mole-
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cular level [13]. The most completely characterized func-
tions for relaxin are in pregnancy, where it inhibits uterine
contraction, induces softening of the birth canal, and
induces lengthening of the interpubic ligament, largely
by inducing extracellular matrix (ECM) remodeling (see
[12] for review). Further studies have suggested that
relaxin may also act as an antifibrotic agent in a number
of tissues. Treatment with relaxin restored the normal
phenotype after experimentally-induced fibrosis in mouse
lung [14] and in rat kidney [15]. Similar results were found
in two other fibrosis models, capsule formation around
implanted osmotic pumps and polyvinyl alcohol sponges
[16]. In clinical trials in humans, relaxin was shown to have
some beneficial effects on patients suffering from scler-
oderma, a condition characterized by excessive fibrosis of
skin and vascular tissues [17]. Recently, relaxin-null mice
were found to develop pulmonary fibrosis with aging,
suggesting that relaxin functions as a protective agent
against fibrosis [18]. Consistent with its mechanism of
action in pregnancy, the antifibrotic actions of relaxin are
based on extracellular matrix remodeling. In lung and
dermal fibroblasts, relaxin was shown to decrease TGF-
b-induced collagen type I secretion, increase MMP-1
expression, and decrease expression of a TIMP [14,19].
In dermal fibroblasts studies, relaxin increased collagenase
expression and decreased TGF-b-induced collagen synth-
esis. Interestingly, in studies using scleroderma fibroblasts,
relaxin inhibited collagen synthesis in the absence of TGF-
b [20]. Since these cells, like activated HSC, produce
elevated levels of collagen, this finding raises the possibi-
lity that relaxin may reverse the disease phenotype.
In light of the studies detailed above, relaxin appears to
act as an antifibrotic agent primarily by inhibiting type I
collagen deposition and promoting matrix degradation.
These qualities are ideal for a fibrosis-reversing agent.
Indeed, there had been speculation that relaxin might be
effective as a hepatic antifibrotic agent [1,21,22]. A recent
study reported that relaxin reduced total collagen, TIMP-1,
and TIMP-2 expression in HSC, and reduced total collagen
in fibrotic rats treated with relaxin [23]. In this study, we
confirm that relaxin reduces total collagen in cultured
HSC, and furthermore show evidence that relaxin increases
collagenase activity, decreases SMA levels, and specifi-
cally decreases type I collagen production by HSC.
2. Materials and methods
2.1. Cell culture
Rat HSC were isolated from SAS Sprague–Dawley rats
(300–350 g) using sequential perfusion with pronase and
collagenase, followed by density gradient centrifugation in
Larcoll [24]. Cell viability was monitored by trypan blue
exclusion, and HSC identified by their typical morphology
and the presence of fat droplets under UV illumination. The
HSC were maintained in DMEM/Ham’s F12 medium
supplemented with 10% fetal bovine serum, 2 mM gluta-
mine, 100 U/mL penicillin and 100 mg/mL streptomycin at
378 in a humidified 5% CO2 atmosphere. The medium was
changed 24 hr after seeding and every 48 hr thereafter.
Within 7–10 days, the HSC displayed the activated (myo-
fibroblastic) phenotype identified by the loss of lipid
droplets and the expression of SMA by Western blot
(see below). At confluence, the cells were suspended using
trypsin/EDTA and subcultured. All cells were used
between passages 5 and 20, since after this point they
gradually lost their relaxin sensitivity. Purified porcine
relaxin was obtained from A.F. Parlow and the National
Hormone & Peptide Program. Cells were treated with
relaxin (0.01–100 nM) for 24–48 hr as indicated below.
2.2. Measurement of total collagen content
Total collagen levels were determined by a modification
of the method of Jimenez et al. [25], which allows simul-
taneous determination of collagen and total protein by the
differential binding of Sirius Red and Fast Green FCF,
respectively. Briefly, subconfluent HSC in 24-well plates
were treated with relaxin for 48 hr in the presence of serum.
The cells were fixed briefly with 4% buffered formalin, and
then stained for 15 min with 0.01% Fast Green FCF in 0.5%
picric acid. After washing, the cells were stained with
0.04% Fast Green FCF and 0.1% Sirius Red (Direct Red
80) in 0.5% picric acid for 15 min. After washing, the bound
dye was solubilized in 50 mM NaOH in 50% methanol, and
absorbance determined at 540 and 630 nm to determine
Sirius Red and Fast Green FCF binding, respectively.
2.3. Determination of type I collagen
HSC in 24-well plates were treated with relaxin in
serum-free medium containing 0.1% BSA, 50 mg/mL
ascorbate and 80 mg/mL aminopropionitrile for 24 hr,
and the conditioned medium collected. The treatment
was limited to 24 hr to minimize the duration of serum-
free conditions in the cultures. The level of type I collagen
was determined by an ELISA procedure [26]. Briefly, 96-
well plates were coated with conditioned media from
relaxin-treated cells, then probed with rabbit anticollagen
I antibody (Biodesign Intl.) followed by an alkaline phos-
phatase-conjugated goat antirabbit IgG. Color develop-
ment was performed using p-nitrophenyl phosphate, and
the absorbance read at 405 nm. Purified rat tail collagen I
(Sigma) was used as the standard.
2.4. Determination of collagen synthesis rate
The effect of relaxin on the rate of collagen synthesis was
determined by the incorporation of 3H-proline into col-
lagenase-digestible proteins essentially as described [27].
Briefly, HSC in 24-well plates were treated with relaxin for
868 R.G. Bennett et al. / Biochemical Pharmacology 66 (2003) 867–874
24 hr, then the medium changed to 0.5 mL per well fresh
medium containing 10% FBS, relaxin, 1 mCi/mL L-[2,3,4,5-
3H]-proline (American Radiolabeled Chemicals), 50 mg/
mL ascorbate and 80 mg/mL aminopropionitrile for 24 hr,
then the conditioned media were collected. For determina-
tion of noncollagen protein, 200 mL aliquots were incubated
for 3 hr with 10 U/mL purified collagenase III (Advanced
Biofactures) in 33 mM Tris, pH 7.5, containing 50 mM
CaCl2 and 5 mM NEM (300 mL total volume). Proteins
were precipitated by the addition of 20 mL 10% BSA and
75 mL of 50% TCA/0.75% tannic acid. After 30 min on ice,
the samples were centrifuged, and the supernatants dis-
carded. The pellets were washed with ice-cold 10% TCA,
dissolved in 1 N NaOH, and counted. Total protein synth-
esis was determined by processing 200 mL aliquots of
conditioned media as above without incubation with col-
lagenase. Collagen synthesis was calculated as collagen
protein produced as a percent of total protein in 24 hr.
2.5. Detection of MMP activity by substrate zymography
The gelatin and collagen-degrading activities of MMPs
in HSC conditioned media were assessed by gelatin or
collagen substrate zymography [28,29]. Cultures of HSC
were treated with relaxin for 48 hr in the presence of
serum, the conditioned medium collected, diluted 1:3 in
nonreducing SDS–PAGE sample buffer without heating,
then resolved on a 10% polyacrylamide gel containing
either 0.1% gelatin or 0.05% collagen I. After removal of
SDS by immersion in 2.5% (v/v) Triton X-100 over
30 min, the gels were placed in incubation buffer
(50 mM Tris, pH 8.0, 200 mM NaCl, 5 mM CaCl2,
0.06% Brij-35) for 18–24 hr at 378. After staining with
0.2% Coomassie Blue R-250, the amount of MMP activity
was quantified by densitometry.
2.6. Western blotting
HSC in 6-well plates were treated with relaxin for 48 hr
in the presence of serum, washed with ice-cold PBS, then
lysed in 100 mL per well lysis buffer (50 mM Tris, pH 7.4,
containing 0.15 M NaCl, 1.0% Triton X-100, and 0.1 mM
phenylmethylsulfonyl fluoride). Protein content in the
lysates was determined using the bicinchoninic acid assay
(Pierce). Equal amounts of protein (10 mg) were resolved
on 10% SDS–PAGE gels and then transferred to PVDF
membranes. Membranes were probed with an anti-SMA
monoclonal antibody (Sigma) at 1:2000 dilution, followed
by a secondary horseradish peroxidase-conjugated goat
antimouse antibody (Jackson Immunochemicals), and
detection by enhanced chemiluminescence. The levels of
SMA in cell lysates were quantified by densitometry. As a
loading control, membranes were stripped and reprobed for
the presence of a-tubulin using a monoclonal antibody
(Sigma). For detection of secreted proteins, conditioned
media from activated HSC was collected 48 hr after treat-
ment without and with 10 nM relaxin, and were passed
through a Cibracon blue column (Pierce) to remove albu-
min. Samples were concentrated 5-fold using a Centricon-
10 microconcentrator (Amicon) and resolved on either 12
or 10% SDS–PAGE. Immunoblotting for was performed
using monoclonal antibodies specific for TIMP-2 (Calbio-
chem) and MMP-13 (Chemicon) or a polyclonal antibody
for TIMP-1 (Santa Cruz Biotechnology).
2.7. RT-PCR for detection of MMP-13 mRNA
Total RNA was extracted from activated HSC after
treatment without and with relaxin (100 nM) using Trizol
(Invitrogen) according to the manufacturer’s instructions.
Genomic DNA was removed by DNase treatment, and
cDNA was generated using a cloned AMV reverse tran-
scriptase kit (Invitrogen). Samples were analyzed by PCR
for MMP-13 expression using the primers and PCR pro-
gram described previously [30], or for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) using a primer set
(Clontech). Samples were resolved on agarose gels and
products detected by ethidium bromide staining.
2.8. Cell proliferation assay
The effect of relaxin on the rate of cell growth was
determined by the incorporation of radiolabeled thymi-
dine. Subconfluent cultures of HSC in 24-well plates were
treated with relaxin for 48 hr in the presence of serum. For
the final 4 hr of treatment, cells received 0.1 mCi/mL [6-
3H]-thymidine (Amersham). After the labeling period, the
cells were washed three times with PBS, then treated with
0.25 mL 10% trichloroacetic acid (TCA) to precipitate the
DNA. The supernatants were removed, and the wells
washed with 2% TCA. The precipitate was solubilized
in 0.25 mL 0.1 M NaOH 0.1% SDS solution, and counted.
Data are expressed as the percent incorporation of thymi-
dine compared to untreated cells.
2.9. Statistics
All data are expressed as mean SE. Comparisons for
differences between groups were made by ANOVA with
Tukey’s post-test. P < 0:05 was interpreted as significant.
Curve-fitting was performed using GraphPad Prism 3.0
software package.
3. Results
When HSC are grown on plastic, they display the
activated phenotype within 7–10 days, characterized by
expression of SMA. Relaxin treatment of HSC for 48 hr
decreased SMA levels as detected by Western blotting in a
dose-dependent manner (Fig. 1). The inhibition of SMA
level was detectable at 0.1 nM relaxin, and a maximum
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decrease of approximately 40% was seen at 1 nM relaxin.
No obvious morphological changes in the cells were
observed after relaxin treatment. To explore the possibility
that decreased SMA was due to decreased cell prolifera-
tion, relaxin-treated cells were metabolically labeled with
3H-thymidine, and the rate of thymidine incorporation into
DNA determined. Relaxin treatment had no significant
effect on the cell proliferation rate (Fig. 2). Thus, the
inhibitory effect of relaxin on SMA levels was not due
to inhibition of the cellular growth rate.
Activation of HSC is also characterized by an elevation
in collagen levels. The effect of relaxin on the level of total
collagen by HSC was determined by Sirius Red/Fast
Green FCF staining. Relaxin treatment for 48 hr induced
a dose-dependent reduction in total collagen content as a
function of total protein (Fig. 3). The maximal decrease
achieved was approximately 30%. The half-maximal inhi-
bitory dose of relaxin was 1.2 nM, consistent with the
action of relaxin through its receptor [13]. To determine if
relaxin influences the rate of new collagen synthesis in
HSC, cells were treated with relaxin for 48 hr, and were
metabolically labeled with 3H-proline for the final 24 hr.
The collagen production was determined by the amount of
collagenase-sensitive radiolabeled protein. Relaxin treat-
ment caused a dose-dependent decrease in the rate of
collagen synthesis (Fig. 4), suggesting that the reduction
Fig. 1. Relaxin decreases SMA levels in HSC. (A) Lysates were prepared
from HSCs treated with the indicated concentrations of relaxin for 48 hr.
The presence of smooth muscle a-actin (SMA) was detected by Western
blotting. As a loading control, blots were stripped and reprobed for
a-tubulin. (B) The SMA content in cell lysates was quantified by
densitometry. Data are expressed as percent of SMA present without
relaxin (mean SE, N ¼ 3, P < 0:05).
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Fig. 2. The effect of relaxin on DNA synthesis by HSC. HSC cultures
were treated with relaxin for 48 hr. For the final 18 hr, cells were
metabolically labeled with 3H-thymidine. The DNA was solubilized and
counted. Data are expressed as the percent incorporation of 3H-thymidine
compared to untreated cells (mean SE, N ¼ 3).
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Fig. 3. Relaxin decreases HSC total collagen content. HSC were treated
with relaxin for 48 hr then fixed in formalin. The collagen content was
then measured by differential staining with Sirius Red and Fast Green FCF.
Data are expressed as mg collagen per mg total protein (mean SE, N ¼ 3,
P < 0:05, P < 0:01).
0 .01 0.1 1.0 10 100
0
20
40
60
80
100
* *
Relaxin (nM)
%
 B
as
eli
n
e 
C
ol
la
ge
n
 S
yn
th
es
is
Fig. 4. Relaxin decreases collagen synthesis by HSC. HSC cultures were
metabolically labeled with 3H-proline for 24 hr in the presence of relaxin,
ascorbate and aminopropionitrile. Proteins were incubated without and
with bacterial collagenase. Data are expressed as the percent collagen-
sensitive radiolabeled material compared with untreated cells (mean SE,
N ¼ 3, P < 0:05).
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in total collagen is due at least in part to a decrease in
overall collagen synthesis.
While the level of total collagen increases with HSC
activation, a qualitative shift also occurs, resulting in an
increase in interstitial (e.g. type I) over the basement mem-
brane-type collagens. Therefore, the effect of relaxin on type
I collagen production by HSC was specifically determined
by ELISA. Relaxin treatment for 24 hr resulted in a 20%
maximal decrease in the level of type I collagen in cultured
HSC (Fig. 5). As in the above experiments, the effect was
dose-dependent and the effective dose was consistent with
action through the relaxin receptor. Thus, relaxin decreased
the production of a fibrillar collagen by activated HSC.
Collagen levels are regulated not only by synthesis and
secretion, but also by degradation by the matrix metallo-
proteinases (MMPs). Activation of HSC is characterized
by decreased production of interstitial collagenase [7]. The
effect of relaxin on collagen-degrading MMP activities
was examined by collagen substrate zymography (Fig. 6).
In the absence of relaxin, there were no collagen-degrading
MMPs detectable other than those present in serum.
Relaxin treatment resulted in a dramatic increase in a band
migrating at approximately 60 kDa, consistent with the
migration of rat pro-MMP-13, the rodent interstitial col-
lagenase [31]. When the data were quantified by densito-
metry, relaxin treatment caused a dose-dependent increase
in the collagenase, with a maximal 25-fold increase at
1 nM. Thus, relaxin treatment induced an increase in
collagenase, which may contribute to the decrease in
overall collagen content. Similar experiments were per-
formed using gelatin substrate zymography, which predo-
minantly measures the activity of the 72 kDa gelatinase A
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Fig. 5. Relaxin decreases type I collagen levels. HSC cultures were treated
with relaxin for 24 hr in serum-free medium in the presence of ascorbate
and aminopropionitrile. The conditioned medium was collected and
analyzed for type I collagen content by ELISA. Data are expressed as
percent of type I collagen content in untreated cells (mean SE, N ¼ 4,
P < 0:01). The actual baseline collagen I concentrations ranged from 38
to 54 mg/mL.
Fig. 6. Relaxin effect on collagenase and gelatinase activity in HSC
cultures. (A) Conditioned media were collected from HSCs treated with
relaxin for 48 hr. The media were subjected to collagen I (top panel) or
gelatin (bottom panel) substrate zymography under nonreducing conditions.
(B) The band of collagenase activity migrating at 60 kDa was quantified
by densitometry. Data are expressed as fold-increase in collagenase activity
over baseline (mean SE, N ¼ 3, P < 0:05, P < 0:01).
Fig. 7. Relaxin effect on expression of MMP-13 and secretion of MMP-13
and TIMPs. (A) Total RNA from HSC treated without () and with (þ)
100 nM relaxin was analyzed by RT-PCR for expression of MMP-13 or
GAPDH as described in Section 2. The colors of the figure are inverted for
easier viewing. (B) 48-hr conditioned medium from HSC treated without
() and with (þ) 10 nM relaxin was analyzed by Western blotting for
MMP-13, TIMP-1 or TIMP-2 as described in Section 2.
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(MMP-2) and the 92 kDa gelatinase B (MMP-9). Relaxin
treatment had no effect on the activity of these gelatinases.
To determine more directly if the collagenase activity
detected above was due to MMP-13 expression, total RNA
from treated and untreated HSC were analyzed by RT-PCR
(Fig. 7A). In the absence of relaxin, expression of MMP-13
was virtually undetectable. Relaxin treatment resulted in a
clear increase in MMP-13 expression. To analyze the
secretion of MMP-13, conditioned media from HSC trea-
ted without and with relaxin was analyzed by Western
blotting (Fig. 7B). In the absence of relaxin, a very low
level of MMP-13 was detected, while relaxin treatment
caused an increase in MMP-13. In the same samples, the
secretion of TIMP-1 was markedly decreased with relaxin
treatment, while TIMP-2 secretion was decreased mod-
estly.
4. Discussion
The successful treatment of hepatic fibrosis hinges on
the removal of damaging excess extracellular matrix. Since
activated HSC play a major role in the production of
collagen, agents that reduce or reverse the activated phe-
notype are prime candidates for therapeutic agents.
Relaxin has demonstrated antifibrotic action in a number
of cells and tissues, including lung, skin, and kidney [14–
16], and recently liver [23]. These effects appear to be due
at least in part to effects on fibroblasts, and include reduced
ECM production and increased matrix degradation.
Because HSC are the matrix-producing fibroblastic cell
type involved in hepatic fibrosis, we sought to determine
the effect of relaxin on activated HSC.
Relaxin was shown to reduce the level of SMA, a marker
of HSC activation. The increased expression of SMA is
postulated to contribute to HSC contractility, a process
involved in portal hypertension [4]. Therefore, relaxin
treatment may also be of benefit in the treatment of portal
hypertension. The decrease in SMAwas not due to impaired
cell proliferation, as relaxin had no effect on DNA synthesis
by HSC. The activation of HSC is also accompanied by
elevated collagen secretion. With relaxin treatment of HSC,
the total collagen content, collagen synthesis, and type I
collagen levels were decreased. Thus, relaxin inhibited the
primary element responsible for the production of fibrillar
matrix in liver injury. Since the level of SMA in the cells
was also decreased, relaxin may be acting to reverse HSC
activation and to restore the quiescent phenotype.
While a reduction in collagen production is beneficial,
the removal of fibrillar collagen is necessary for the repair
of hepatic fibrosis. In the recovery stage of experimental
hepatic fibrosis, a large induction of MMP-13 expression
was detected [30], suggesting that MMP-13 is an integral
part of the antifibrotic process. In HSC cultures, relaxin
increased the expression and secretion of MMP-13. At the
same time, the secretion of TIMP-1 and TIMP-2 was
decreased, consistent with an earlier report [23]. The
reduction in TIMP levels would result in elevated MMP
activity. Therefore, relaxin acts on HSC in a two-pronged
manner, first by reducing HSC markers of HSC activation
(reduced the production of collagen and SMA by HSC),
and second by promoting fibrillar matrix degradation by
elevating collagenase activity. The result is a shift in the
HSC from a phenotype that contributes to fibrosis to one
that promotes recovery.
The results demonstrating relaxin reduction of total
collagen content and collagen synthesis are in good agree-
ment with the results of a recently published study exam-
ining relaxin effects on HSC cultures [23]. However, that
study detected no effect of relaxin on the expression of
SMA, type I collagen, or MMP-13 mRNA as determined
by Northern blotting. This raises the possibility that the
changes in some of these proteins may not be reflected at
the transcriptional level, although we were able to detect
increased MMP-13 by a different technique (RT-PCR).
Alternatively, it may be possible that the different sources
of relaxin (recombinant human relaxin vs. the purified
native porcine used in this study) may have variable effects
on rat HSC. Indeed, there is only 40–70% homology of
relaxin sequences across species [12], and relaxins from
different species have demonstrated variable effects in
tissues [32].
The effective concentration of relaxin required for all
effects was consistent with action through the newly iden-
tified relaxin receptors LGR7 and LGR8 [13]. Of these,
LGR7 expression was detected in whole liver mRNA.
Interestingly, unlike insulin receptors, relaxin receptors
are both 7-transmembrane spanning, G-protein-coupled
receptors, which act via a pathway involving cAMP. It is
interesting to note that an increase in the levels of cAMP in
HSC decrease some markers of HSC activation [33–35].
Therefore, the mechanism of action of relaxin in stellate
cells is likely through one or both of the relaxin receptors
through elevation of cAMP. Preliminary studies have sug-
gested that activated HSC express LGR7 and possibly
LGR8 as well (data not shown). Studies are currently
underway to characterize the relaxin receptors in HSC,
and to determine the signaling properties of relaxin.
There is considerable evidence that liver fibrosis is a
reversible condition. In a number of clinical situations, such
as autoimmune disease and hepatitis B and C after success-
ful treatment, a restoration to nearly normal cell architec-
ture was observed, suggesting that the mechanisms exist to
clear tissue scarring (reviewed in [36]). This concept has
been supported in experimental animal models of liver
fibrosis. In CCl4-induced fibrosis after CCl4 withdrawal,
and in the bile duct ligation model after bilioduodenal
anastomosis, liver architecture was returned to nearly nor-
mal [30,37–39]. The recovery phase is accompanied by a
change in the ECM remodeling to favor the restoration of
the basement membrane-type ECM. Contributing to the
resolution of fibrosis is a decrease in collagen expression
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[37,38]. In addition, an increased in interstitial collagenase
expression as well as decreased in TIMP expression were
seen during the recovery stage [30,37]. The ultimate result
is that the balance between deposition and degradation of
collagen I was restored to a collagen I-degrading environ-
ment. It is still unclear what mechanisms may be involved in
the ‘‘inactivation’’ of HSC, but there is evidence that apop-
tosis of activated HSCs may be involved in recovery from
experimentally-induced fibrosis [37]. Alternatively, some
reports have shown evidence that activated HSCs may
revert to a quiescent phenotype. Treatment of culture-acti-
vated HSC with interferon-g decreased markers of HSC
activation, including proliferation and the expression of
collagen and SMA [40]. Other studies showed that ligands
of peroxisome proliferator-activated receptor-g resulted in
a decreased collagen synthesis and SMA expression, and a
simultaneous increase in MMP-13 expression, with no
evidence of apoptosis [41,42]. Finally, a recent study
demonstrated reversion of activated HSC to a quiescent
phenotype by growth on basement membrane substratum
[43]. These findings suggest that reversal of HSC activation
is possible, and thus an attractive target for fibrosis treat-
ment. In the present study, relaxin inhibited myofibroblastic
properties of HSC, but had no effect on cell proliferation,
and moreover stimulated secretion of collagenase. There-
fore, it seems likely that relaxin acts to reverse HSC activa-
tion rather than by the induction of apoptosis. In conclusion,
the studies presented here suggest that a candidate agent for
reversal of HSC activation and possible therapeutic treat-
ment of hepatic fibrosis is the hormone relaxin.
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